Antibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [4]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11-2239-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD223 (LAG-3) Monoclonal Antibody (3DS223H), FITC, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: This 3DS223H monoclonal antibody recognizes human CD223 also known as Lymphocyte Activation Gene 3 (LAG-3). LAG-3 is a 70-kDa surface glycoprotein belonging to the Ig superfamily with homology to CD4. LAG-3 binds to MHC class II with higher affinity than CD4 and is thought to be involved in the negative regulation of T cell activation and homeostatic proliferation. Surface expression of LAG-3 has been reported on activated T cells (including regulatory T cells) and NK cells. CD8+ T cells usually express LAG-3 at significantly higher levels than CD4+ T cells. Coexpression of LAG-3 and CD49b has been proposed to identify human and mouse Type 1 regulatory T cells (Tr1 cells).
- Conjugate
- Green dye
- Antibody clone number
- 3DS223H
- Concentration
- 5 µL/Test
Submitted references Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15.
MAVS Genetic Variation Is Associated with Decreased HIV-1 Replication In Vitro and Reduced CD4(+) T Cell Infection in HIV-1-Infected Individuals.
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma.
A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.
OMIP-037: 16-color panel to measure inhibitory receptor signatures from multiple human immune cell subsets.
Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection.
Fernandez RA, Mayoral JE, Pierre-Louis L, Yao Y, Xu Y, Mu S, Martinez-Lopez J, Primo D, Miyazaki T, Prabhala R, Anderson KC, Overwijk WW, Munshi NC, Fulciniti M
Blood advances 2023 Jan 10;7(1):9-19
Blood advances 2023 Jan 10;7(1):9-19
MAVS Genetic Variation Is Associated with Decreased HIV-1 Replication In Vitro and Reduced CD4(+) T Cell Infection in HIV-1-Infected Individuals.
Stunnenberg M, van Pul L, Sprokholt JK, van Dort KA, Gringhuis SI, Geijtenbeek TBH, Kootstra NA
Viruses 2020 Jul 16;12(7)
Viruses 2020 Jul 16;12(7)
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma.
Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed N
Nature communications 2020 Jul 15;11(1):3549
Nature communications 2020 Jul 15;11(1):3549
A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.
Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, Savic Prince S, Wiese M, Lardinois D, Ho PC, Klein C, Karanikas V, Mertz KD, Schumacher TN, Zippelius A
Nature medicine 2018 Jul;24(7):994-1004
Nature medicine 2018 Jul;24(7):994-1004
OMIP-037: 16-color panel to measure inhibitory receptor signatures from multiple human immune cell subsets.
Belkina AC, Snyder-Cappione JE
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2017 Feb;91(2):175-179
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2017 Feb;91(2):175-179
Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection.
Miles B, Miller SM, Folkvord JM, Kimball A, Chamanian M, Meditz AL, Arends T, McCarter MD, Levy DN, Rakasz EG, Skinner PJ, Connick E
Nature communications 2015 Oct 20;6:8608
Nature communications 2015 Oct 20;6:8608
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Normal human peripheral blood cells were stimulated for 3 days with Human IL-2 Recombinant Protein (Product # 14-8029-81), Anti-Human CD3 (Product # 16-0037-81), and Anti-Human CD28 Functional Grade Purifieds (Product # 16-0289-81). These cells were then surface stained with Anti-Human CD8a PE-Cyanine7 (Product # 25-0088-42) and Mouse IgG1 K Isotype Control FITC (Product # 11-4714-42) (left) or Anti-Human CD223 (LAG-3) FITC (right). Cells in the lymphocyte gate were used for analysis.
- Conjugate
- Green dye
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 T FR exhibit an enhanced regulatory phenotype in ex vivo HIV infection. Tonsil cells were mock-, X4-, or R5-spinoculated and cultured under experimental conditions as indicated. T FR were then analysed for expression of regulatory receptors and cytokine production by intracellular cytokine staining. ( a ) Percentage of total (surface and intracellular) T FR CTLA-4 expression ( n =15). ( b ) Percentage of surface T FR LAG-3 expression ( n =8). ( c ) Production of IL-10 by T FR ( n =7). ( d ) Production of TGF-beta-1 (measured as LAP) by T FR ( n =5). The horizontal bars of each graph indicate the median value and are listed where appropriate for clarity. Statistical analyses were performed by Friedman ( a , b ) or Mann-Whitney tests ( c , d ) and significance is denoted by asterisks where * P
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 MAVS genetic variation does not affect T cell exhaustion, activation, and senescence. ( a ) Percentages of PD-1 + , LAG-3 + , CD38 + , HLA-DR + , CD134 + , exhausted (PD-1 + LAG-3 + ), activated (CD38 + HLA-DR + ), and senescent (CD27 - CD28 - ) cells within CD4 + and ( b ) CD8 + T cells of untreated HIV-1-infected individuals with a MAVS minor or MAVS major genotype 2.5-3.5 years p.SC were analyzed using flow cytometry. Each square or dot represents a different study participant (median +- IQR). No significant differences between HIV-1-infected individuals with a MAVS minor or MAVS major genotype were observed.
- Conjugate
- Green dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 MAVS minor genotype is associated with a decreased percentage of naive CD4 + T cells. ( a ) Percentages and ( b ) cell counts of naive (T naive ; CD45RA + CD27 + CCR7 + ), terminally differentiated effector memory (TEMRA; CD45RA + CCR7 - CD27 - ), central memory (CM; CD45RA - CCR7 + CD27 + ), transitional memory (TM; CD45RA - CCR7 - CD27 + ), and effector memory (EM; CD45RA - CCR7 - CD27 - ) cells within CD4 + and CD8 + T cells were analyzed using flow cytometry. ( c ) Percentages of exhausted (PD-1 + LAG-3 + ) and activated (CD38 + HLA-DR + ) CD4 + T cells and ( d ) CD8 + T cells within T naive , TEMRA, CM, TM, and EM populations were analyzed using flow cytometry. Each square or dot represents a different study participant (median +- IQR). All significant differences are indicated: * p < 0.05, unpaired Mann-Whitney test.
- Conjugate
- Green dye